Pharmaceutics_R&D
Follow
Find tag "R&D"
3.8K views | +4 today
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

Plombée en France, l’industrie pharmaceutique se lamente toujours

Plombée en France, l’industrie pharmaceutique se lamente toujours | Pharmaceutics_R&D | Scoop.it

En croissance grâce à ses exportations, l’industrie du médicament voit son marché français chuter. Et se dit victime des plans d’économies pour la sécurité sociale et de multiples taxes. Alors même qu’un député veut lui en imposer une nouvelle, pour la recherche dans le cancer des enfants… (...) - L'Usine Nouvelle, 14/06/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s | Pharmaceutics_R&D | Scoop.it

US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data.

The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013

more...
NCTC's curator insight, March 29, 2013 4:19 AM

Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.

Rescooped by Julien Hering, PhD from All about Pharma by Pharmacomptoir
Scoop.it!

Big pharma companies must push for medication adherence

Big pharma companies must push for medication adherence | Pharmaceutics_R&D | Scoop.it

Pharmaceutical companies lose an estimated $188 billion annually in revenues in the U.S. because patients fail to take their prescribed medications, according to a study by consulting firm Capgemini.

 

Even for the countries in Western Europe such as the Netherlands where medication is fully covered, adherence is still a major concern and growing issue.

 

In the U.S. Medicare payment reforms aim to place an emphasis on preventive health measures affecting other sectors in health care, pharmaceutical companies are no longer alone in facing poor medication adherence.

 

The question is are these false promises or actual achievable objectives because of wrong targeting?

 


Via Lionel Reichardt / le Pharmageek, Rémy TESTON, Pharmacomptoir / Corinne Thuderoz
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Does pharma spend more on marketing than R&D? A numbers check

Does pharma spend more on marketing than R&D? A numbers check | Pharmaceutics_R&D | Scoop.it

So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.

Derek Lowe's blog dug up the numbers and calculated spending as a percentage of revenue. In the case of R&D, that's pretty easy to determine; companies break that number out as its own line item. As for marketing, sales expenses are lumped into a category dubbed SG&A, or sales, general and administrative expenses. And as Lowe notes, that category includes lots more than sales spending. Executive salaries, for instance. (...) - by Tracy Staton, FiercePharma, May 21, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Roche Bets On Early-Stage Alzheimer’s: Luca Explains

Roche Bets On Early-Stage Alzheimer’s: Luca Explains | Pharmaceutics_R&D | Scoop.it
In recent months, Alzheimer’s compounds have been hot news. Pfizer and Johnson & Johnson had one that flopped. Eli Lilly released mixed study results that generated a mix of hype and hope. And Merck (back stories here, here and here). And Merck is betting on one in a test with patients suffering mild to moderate symptoms. Meanwhile, another big drugmaker, Roche, is chugging along with a few compounds of its own and hopes its focus on early-stage disease will prove correct. We spoke briefly with Luca Santarelli, the head of neuroscience at Roche, about its efforts… (...) - Pharmalot, By Ed Silverman, December 11th, 2012
more...
No comment yet.